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Abstract: Pre-school age children account for 10%–20%
of the 2 billion people worldwide who are infected with
soil-transmitted helminths (STHs): Ascaris lumbricoides
(roundworm), Trichuris trichiura (whipworm), and Ancylos-
toma duodenale/Necator americanus (hookworms).
Through a systematic review of the published literature
and using information collated at World Health Organi-
zation headquarters, this paper summarizes the available
evidence to support the recommendation that pre-school
children should be included in regular deworming
programmes. The first section describes the burden of
STH disease in this age group, followed by a summary of
how infection impacts iron status, growth, vitamin A
status, and cognitive development and how STHs may
exacerbate other high mortality infections. The second
section explores the safety of the drugs themselves, given
alone or co-administered, drug efficacy, and the impor-
tance of safe administration. The third section provides
country-based evidence to demonstrate improved health
outcomes after STH treatment. The final section provides
country experiences in scaling up coverage of pre-school
children by using other large scale public health
interventions, including vitamin A programmes, immuni-
zation campaigns, and Child Health days. The paper
concludes with a number of open research questions and
a summary of some of the operational challenges that still
need to be addressed.
Introduction
It is well known that pre-school-age children (PSAC) pay the
highest toll of mortality and morbidity for the ‘‘high profile’’
diseases: it is estimated that more than 10 million children die
every year from malaria, acute respiratory infections, diarrhoea,
HIV/AIDS, vaccine-preventable diseases (including measles and
tetanus), and from malnutrition and neonatal complications before
reaching their 5th birthday [1]. Young children also pay heavily
for some of the less well-known diseases, including infection with
one or more of the soil-transmitted helminths (STHs): Ascaris
lumbricoides (roundworm), Trichuris trichiura (whipworm), and
Ancylostoma duodenale/Necator americanus (hookworms).
PSAC comprise between 10% and 20% of the 3.5 billion people
living in STH-endemic areas [2], and although these infections are
not among the big killers, they endanger children’s health in a
subtle and debilitating way. Chronic infections compromise
healthy growth, cognitive development, physical fitness, and iron
status, and affect the immune response of infected children.
Growth faltering typically occurs between 6 months and 2 years
of age, overlapping with the time when STH infections begin to
establish themselves. Globally it is estimated that almost 200
million PSAC are stunted, 33% of whom live in developing
countries; STH infections are an important factor contributing to
malnutrition in this age group [3].
From the health perspective, there is now ample evidence
clearly demonstrating that regular treatment of helminth infections
produces immediate as well as long-term benefits, significantly
contributing to the development of affected individuals, particu-
larly children [4–6]; from the operational perspective, several
issues have also strengthened the argument for including
anthelminthic drugs in large scale public health interventions:
the drugs are safe and simple to administer, although training for
the drug administrators is essential, particularly when very young
children are being targeted [7,8]. Anthelminthic drugs are popular
with affected communities, which boosts compliance and therefore
increases the overall coverage of interventions. STH treatment is
also one of the key components of the preventive chemotherapy
package concept [9]. With regard to the costs and benefits of STH
deworming, the best evidence relates to school-age children (SAC)
since they are easy to reach en masse through the school system,
making it a low-cost intervention, while treatment of this group
produces substantial returns in terms of reduced morbidity,
improved growth, and improved educational outcomes [10].
The same economies of scale are likely to exist for younger
children who are increasingly being reached through large scale
interventions, including vitamin A campaigns, vaccination pro-
grammes, and Child Health Days [2,11].
In sum, recent recommendations encourage governments and
policy makers to invest in helminth control as an asset for
development [6]. Like any public health intervention, however,
deworming for STH infections must be justified by evidence and
judiciously implemented, especially when very young children are
targeted for treatment.
This review summarizes state-of-the-art published data and
information collected through WHO’s Global Database on STHs
on the evidence behind treating PSAC for STH infections. Since
there is no consistent definition of PSAC in the medical literature
in terms of age and/or school enrolment, we have used age as the
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www.plosntds.org 1 March 2008 | Volume 2 | Issue 3 | e126key defining indicator in this review; thus, any child between 1 and
5 years inclusive (i.e., between the 1st and the 6th birthday) was
considered a PSAC irrespective of his/her school enrolment status.
Children in their first year of life are considered as infants and
children from their 6th birthday up to the age of 15 years inclusive
(i.e., up to their 16th birthday) are considered to be school-age
children.
Burden of Disease Associated with STH Infections in
PSAC
Numbers Infected. STH infections are widespread globally.
Asthe prevalence and intensity of infection peaks inschool age, SAC
have traditionally been the priority target group for treatment.
Nevertheless, as soon as an infant starts to explore its environment,
thus coming into contact with contaminated soil, he/she is at risk of
infection according to the levels of transmission in the area.
Recent estimates indicate that more then 2 billion people are
infected with STHs worldwide, a significant proportion of which
are PSAC (Table 1). A selection of studies that have reported STH
prevalence data in children disaggregated by age group is shown in
Table 2.
The first years of a child’s life are marked by intense physical and
mental development. In resource-poor settings, this development is
compromised by a number of factors, including worm infections
that exacerbate already high levels of anaemia and wasting
malnutrition.Belowaresome ofthemost commonhealth indicators
affected by chronic STH infections: iron status, nutrition and
growth, vitamin A status, and cognitive development.
Iron Status. In PSAC whose iron stores are already depleted
by malnutrition, additional losses due to hookworms (the most
pathogenic of the three STHs), even at low intensities of infection,
make a significant contribution to further lowering their
haemoglobin levels and triggering anaemia.
Studies in East African PSAC clearly demonstrated a strong
correlation between hookworm infection and anaemia. In a
community in coastal Kenya, severe anaemia was associated with
hookworm infections (.200 eggs per gram) at all ages (range 6–
76 months), in both sexes, and independently of socioeconomic
factors [12]. In Zanzibar, Tanzania, low haemoglobin concentra-
tions were associated with malaria parasitaemia in children
,30 months, and with hookworm intensity in children aged 30–
71 months. Importantly, this study also found an association
between intensity of hookworm infection and other iron deficiency
indicators, such as serum ferritin and erythrocyte protoporphyrin
[13]. Theoretical calculations on the quantity of blood lost through
hookworm infections also concluded that the parasite could be a
leading cause of iron deficiency in PSAC [14].
With regard to T. trichiura, moderate-heavy infections have
similarly been associated with higher anaemia levels, particularly
in malnourished children [15], and co-infection with T. trichiura
Table 2. Published Reports of Prevalence of STH Infections in PSAC Population
Country Sample Size Age Range (Years) Prevalence (%) Reference
Ascaris Trichuris Hookworm
Myanmar 1,206 2–12 81 5 2 [63]
Bangladesh 1,402 2–6 71 44 10 [72]
Indonesia 280 2–5 55 29 0 [91]
Mexico 508 2–10 NS 100 0 [73]
China 329 0–4 66 34 24 [92]
Philippines 544 0–3 3
a,1 9
b 1
a,3 5
b NS [93]
DRCongo (formerly Zaire) 100 0.5–2 66 48 7 [94]
Tanzania (Zanzibar) 467 0.5–6 40 68 51 [13]
India 1,061 1.5–3.4 50 NS NS [65]
Kenya 460 0.5–6 20 15 29 [12]
Brazil 200 2–6 35 13 NS [95]
Ethiopia 7,155 1–4 38 54 10 [96]
Malaysia 272 3–6 20 24 NS [97]
Madagascar 864 0–10 88 43 19 [98]
South Africa 200 4–6 82
c,8 1
d 96
c,5 7
d 44
c,4
d [88]
Ghana 422 1–5 62
c,2 3
d 40
c,2
d 18
c,1 3
d [99]
Nigeria 689 1–5 39 36 43 [100]
aUrban area.
bRural area.
cCoastal area.
dInland area.
NS, not specified.
doi:10.1371/journal.pntd.0000126.t002
Table 1. Estimates of Numbers Infected with STHs [90]
Parasite
Total Infected
(Millions)
Under 5 Years
(Millions)
Ascaris lumbricoides 1221 122
Trichuris trichiura 795 86
Hookworm 740 21
doi:10.1371/journal.pntd.0000126.t001
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although this has only been studied in SAC to date [16].
There is no evidence that A. lumbricoides infection leads to iron
malabsorption and iron deficiency anaemia in children.
Nutrition and Growth. There is now a substantial body of
research that clearly demonstrates how STH infections impair
healthy nutrition [3,5]. Growth in STH-infected children is
compromised through a variety of mechanisms, including
reduced food intake due to malabsorption and/or reduced
appetite [5]. As a result, infected children show higher levels of
stunting [3,14,17]. A study in northeast Brazil showed that in a
cohort of children aged 2–7 years, helminthiasis acquired in early
childhood was associated with a 4.6-cm shortfall at the age of 7
[18]. Even light infections may have a deleterious effect on protein
metabolism, appetite, and erythropoiesis [17]; such effects may be
mediated by cytokines (IL 1, IL 6) that are produced by the body’s
immune response to new helminth infections in naı ¨ve children.
Vitamin A Status. Ascariasis (and trichuriasis in some cases)
is associated with low serum vitamin A (retinol) levels through
different mechanisms [19]. Ascaris lives in the gut, where it
interferes with the absorption of vitamin A [20]. In PSAC whose
diet is already dangerously low in vitamin A, Ascaris infection may
trigger clinical vitamin A deficiency and thus may significantly
contribute to increased morbidity (such as blindness) and
mortality. A study in Nepal found that prevalence of
xerophthalmia—the ocular manifestation of vitamin A
deficiency—was three times higher in Ascaris-infected children
aged 6–120 months than in an uninfected group [21].
Cognitive Development. For obvious reasons, the negative
association between helminth infections and mental performance
has mainly been studied in SAC [22,23]. Yet between birth and
entering school, significant skills are acquired in different domains
that pave the road for the rapid cognitive development that takes
place at around 6 years. Although only one large-scale randomised
study has been carried out in children aged 6–59 months [24], it is
evident that STH infections negatively impact motor and language
development. STH infections early in life may therefore negatively
affect these cognitive indicators when they are measured later in
life [24,25]. Children between 17 and 72 months of age affected
by Trichuris Dysentery Syndrome (TDS), a severe form of
trichuriasis, showed a marked decrease in cognitive score tests
compared with matched controls [26]. This could be due to a
variety of causes, both direct and indirect, including induced
sleeplessness and micronutrient losses, mainly iron. Changes in
cognitive performance may also be plausibly linked with
inflammatory response and cytokines triggered by parasitic
infections, although this is still under study [27].
Acute Consequences. In young children, acute
consequences of STH infections should not be overlooked.
Intestinal obstruction is one of the life-threatening consequences
of Ascaris infections and is most frequent in children ,10 years of
age. It is estimated that 12 million cases occur annually worldwide
with approximately 10,000 deaths. The incidence reported by
published studies is between 0 and 0.25 cases per year per 1,000
population in endemic areas, with a mean case fatality rate of
.5% [28]. TDS, already mentioned above, is another acute
complication associated with heavy Trichuris infection; it mainly
occurs in children and leads to severe growth stunting and
cognitive deficits that might not be reversible despite treatment
[26].
Interactions with Other Infections. Several field-based
observational studies have suggested that STH infections
increase the risk of infection with—and adversely affect the
clinical outcome of—concomitant malaria, tuberculosis, or HIV/
AIDS. Several possible explanatory mechanisms have been put
forward, mainly based on an altered immunological response to
the infection (and to vaccination in the case of tuberculosis) in
individuals who are already infected with STHs. To date, most of
this research has been carried out in older age groups with
contrasting results. However, the available evidence suggests that
treating PSAC for STHs may act as a preventive and possibly a
co-therapeutic measure for these three infections. Further research
is needed to elucidate the complex relationship between STHs and
other infections in co-endemic settings [29–33].
Use of Anthelminthics in Children under 5
Safety. To date, millions of children—including PSAC—
have been routinely administered one or more of the four
anthelminthic drugs recommended for STH treatment:
albendazole, mebendazole, levamisole, and pyrantel. In 2005,
about 48 million PSAC were administered at least one dose of any
of the four drugs (WHO, unpublished data); in 2004, slightly less
than 37 million were covered [2].
Albendazole
At the dosage recommended for STH treatment, the incidence
of side effects following treatment reported in the literature is very
low. Examples include migration of A. lumbricoides through the
mouth, occasional gastrointestinal symptoms (epigastric pain
0.3%, diarrhoea 0.3%, nausea 0.2%, vomiting 0.1%), central
nervous system symptoms (headache 0.2%, dizziness 0.1%), and
rare allergic phenomena (oedema 0.7/1000, rashes 0.2/1000,
urticaria 0.1/1000). All these reactions are minor and transient,
usually spontaneously disappearing within 48 hours from onset
without need for hospitalisation [34,35].
Mebendazole
A few instances of erratic migration of A. lumbricoides, mild
gastrointestinal disturbances, transient abdominal pain, and
diarrhoea have been reported following treatment with mebenda-
zole [34]. Several studies that examined the use of benzimidazoles
in children under 24 months reported no incidence of serious
adverse experiences, and side effects (either reported or actively
searched for) were negligible [4]. The most recent evidence comes
from a placebo-randomised trial where there was no increase in
the incidence of any side effects in children (aged 6–59 months)
treated with mebendazole (500 mg) compared to the control group
[36].
Levamisole
No literature was found specifically on the use of levamisole in
PSAC; however, levamisole has been used for mass administration
in China, Iran, Vietnam, Brazil, Kenya, and Nigeria. Reported
adverse reactions include occasional vomiting (5%), dizziness (3%),
headache (3%), and weakness (2%); all such reactions were mild
and transient [37–39]. No abnormalities in haematological
laboratory tests have been detected with a single dose calculated
on the basis of weight (2.5 mg/kg). There have been, however,
reports of an increased but low risk of demielizing encephalitis in a
large-scale study in China following treatment with levamisole
[40]. Also, in Vietnam, STH treatment with levamisole was
associated with severe central nervous system disorders in 116
cases who were treated with a locally manufactured generic form
of levamisole (Centre for Adverse Drug Reaction, Ministry of
Health, Vietnam, unpublished report). There are reports of some
drug interactions when levamisole is co-administered with
albendazole or ivermectin [41].
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Pyrantel has been extensively used in numerous helminth
control programmes, particularly in Southeast Asia and Latin
America. In a study of 1,506 individuals including children under
5 years of age, side effects were mild and transient and included
occasional diarrhoea (4.3%), abdominal pain (4%), nausea (3.5%),
vomiting (2%), and headache (3%) [42,43]. Temporarily raised
serum transaminase was detected in 2% of patients.
Safe administration
Given the findings that these drugs are extremely well tolerated
by infected and non-infected individuals and whole communities
at risk of STH infections, WHO recommended that it is safe for
paramedical and trained non-medical personnel to administer the
drugs. However, it should be noted that while the drugs themselves
are extremely safe, their administration must also be safe. This is
particularly relevant in campaign settings where hundreds of
young children (usually PSAC) pass through the health posts each
day and multiple products are being administered. Following reports
that some of the youngest children were having difficulty swallowing
the relatively large deworming tablet, WHO carried out operational
research in 2006 to assess the problem. Data from Madagascar and
Rwanda found that 1% and 0.1%, respectively, of the PSAC choked
on the tablet (WHO, unpublished data), which prompted concerns
and interim recommendations from WHO, including the need for
appropriate training when treating this age group and for the tablet
to be broken and crushed with water before administration to
children aged 1–3 years [8]; older children should be asked to chew
the tablets in front of the administrator and children should never be
forced to swallow the tablet, which can cause choking or
asphyxiation (UNICEF Ethiopia, unpublished report); and health
posts must be set uplogically with the products delivered ina specific
order—WHO recommends that the vaccine is given after the
vitamin A and anthelminthic, and a crying child should never be
forced to swallow the tablet [8].
In some countries, suspension formulations are used to treat
PSAC. The drawback is that syrups are more expensive and more
difficult to store and transport [9].
Safety of Co-Administration. Anthelminthic drugs against
STH are now routinely delivered with other anthelminthics, with
vitamin A supplements, and with certain vaccines. Although
pharmacokinetics of anthelminthics has been extensively
investigated [44], no specific studies have evaluated the phar-
macokinetic and clinical drug interactions of STH anthelminthics
with other products when co-administered to either SAC or
PSAC, except for albendazole with praziquantel or DEC; and
pyrantel with oxantel.
Albendazole+diethylcarbamazin
Albendazole and diethylcarbamazin (DEC) for the treatment of
lymphatic filariasis can be administered to children from their 2nd
birthday onwards [9]. No increase in the number of adverse
reactions has been reported as compared to each drug being
delivered alone [45]. As of 2002, the monitoring and evaluation
system of the global programme to eliminate lymphatic filariasis
has reported that 5.3% of those administered with albendazole+-
DEC (all age groups) had experienced an adverse reaction of a
gravity sufficient to prevent normal daily activities [46].
Albendazole+ivermectin
The use of this combination for the treatment of lymphatic
filariasis is restricted to individuals $15 kg in weight or $90 cm
in height [9]. It has been shown that in countries where height is
used as the selection criterion, a large proportion of PSAC is
included in the target population because the threshold height of
the treatment pole (90 cm) often selects children 5 years old and
younger [47]. The monitoring and evaluation system of the global
programme to eliminate lymphatic filariasis reported that as of
2002 a small proportion (1.5%) of those administered with
albendazole+ivermectin (IVM) (all age groups) had experienced
an adverse reaction of a gravity sufficient to prevent normal daily
activities [46].
Pyrantel+oxantel
Pyrantel given with oxantel has proved to be more effective
against STHs than either drug alone [48,49], particularly against
T. trichiura [50]. No serious adverse experiences have been
reported in large-scale helminth control programmes [51].
Albendazole/mebendazole+vitamin A
WHO recommends that any of the two benzimidazoles above
can be safely co-administered with vitamin A supplements [11].
There are no published epidemiological studies investigating the
pharmacological interaction or the clinical safety of co-adminis-
tration of these two products. However, after multiple years where
these two interventions have been co-delivered in countries across
the world, the authors are not aware of any increased frequency of
adverse reactions or serious adverse experiences.
Anthelminthic drugs+vaccinations
As previously mentioned, there is evidence that helminth
infections modulate the immune response to unrelated pathogens,
and they have been implicated in the poor efficacy of some vaccines,
either currently used, for example those against tuberculosis (BCG)
or cholera, or experimental, such as that against malaria [32,52,53].
Conversely,deworming treatment beforeantimalarialimmunization
restored the protective immunity to malaria challenge in nematode-
infected mice [53], showing that anthelminthic treatment might
boost immunological response ininfected children. Although there is
no policy regarding co-administration of anthelminthic drugs and
vaccinations, several large-scale interventions currently deliver
albendazole or mebendazole with measles, polio, or BCG vaccines.
The authors are at present not aware of an increased frequency of
adverse reactions or serious adverse experiences following imple-
mentation of such interventions.
Drug Efficacy—Reducing the Worm Burden
The broad spectrum efficacy of both benzimidazoles, levami-
sole, and pyrantel in reducing the prevalence and intensity of STH
infections has been extensively described [54,55]. Drug efficacy
varies according to a number of variables, including the dose, the
helminth species the parasite strains involved, the transmission and
intensity of infection, the diagnostic method used, and the timing
of assessing efficacy after treatment [56]. However, drug efficacy is
not influenced by age, and therefore it is assumed that results from
efficacy studies in age groups other than PSAC are also applicable
to this age group.
N Formulation and dosages [57,58].
# All four anthelminthics are given as a single dose and are
not recommended in children ,12 months.
# Albendazole (chewable and non-chewable tablets 200 and
400 mg; oral suspension 100 mg/5 ml, 200 mg/5 ml) is
given at the dosage of 400 mg for all ages (except for
children between 12 and 24 months. who receive 200 mg).
Review
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and 500 mg; oral suspension 100 mg/5 ml) is given at a
dosage of 500 mg for all ages.
# Levamisole (chewable tablets 40, 50, and 150 mg; syrup
40 mg/5 ml) is given at the dosage of 2.5 mg/kg.
# Pyrantel (chewable tablets 250 mg; oral suspension
50 mg/ml) is given at the dosage of 10 mg/kg.
N All four anthelminthics are very effective against A. lumbricoides,
with cure rates (CRs) and egg reduction rates (ERRs) between
90% and 100%.
N Albendazole is effective against the hookworms (CR 57%–
95% and ERR 79%–99%) and has been shown to be more
active than other anthelminthics against N. americanus.
N Mebendazole is less effective in curing hookworms than
albendazole, but nevertheless reduces the worm burden by
.80%.
N Levamisole and pyrantel are active against hookworm
infections, although benzimidazoles are the drug of choice in
large scale deworming campaigns. Levamisole is less effective
in curing infections, and both drugs have been shown to be
more effective against A. duodenale (ERR.80%) than against N.
americanus, where repeated doses are needed, especially in
heavy infections.
N Both benzimidazoles (albendazole and mebendazole) have
similarly poor efficacy in curing T. trichiura infections (CR
between 10% and 77%), but significantly reduce the worm
burden (ERR 60%–80%).
N Levamisole and pyrantel have little effect on T. trichiura.
It is essential to recognise that in endemic areas, re-infection is
the rule and the objective of regular deworming is not to cure since
re-infection is inevitable, but to reduce and keep the worm burden
of infected individuals below the threshold that is associated with
morbidity [59]. There is the threat that after several anthelminthic
treatments, drug efficacy may be impaired due to selection of
resistant parasites. Anthelminthic resistance is not yet a public
health problem in human STHs; nevertheless, drug efficacy should
be monitored where large-scale deworming programmes are in
place [60]. In 2006, a study to investigate the efficacy of
albendazole in PSAC was carried out in Nepal, where the drug
has been regularly delivered over the past 5 years. No sign of
reduced efficacy due to drug resistance was found (Marco
Albonico, personal communication).
The Health Impact of Regular STH Deworming in
Endemic Areas
Periodic STH deworming has been shown to improve growth,
micronutrient status (iron and vitamin A), and motor and language
development in PSAC, and makes a strong case for including this
age group in control programmes where STH helminth infections
are prevalent. Below we describe the effectiveness of the drugs in
reducing morbidity. It is worth noting that some of the trials
described included a passive or active pharmacovigilance
component, which further confirms the safety of administering
anthelminthic drugs to this age group.
Impact on Morbidity. Unlike some other parasitic
infections, morbidity attributable to STHs is often subtle and
non-specific, and therefore difficult to assess. Typical symptoms
include vomiting, coughing, and abdominal pain. In some cases,
more specific signs such as passing worms are observed. The
frequency of all these symptoms in PSAC and SAC infected with
A. lumbricoides in rural Myanmar was drastically reduced by 6-
monthly treatment with levamisole [61].
Taking each of the morbidity indicators most associated with
STH infections in turn:
Growth
A summary of published studies that demonstrate the
improvement in growth of PSAC after anthelminthic treatment
is shown in Table 3.
In Tanzania, PSAC had a demonstrable growth benefit when
they received repeated treatment with levamisole for their Ascaris
infections [62].
In Myanmar, 3-monthly levamisole treatment resulted in greater
weight (0.93 kg) and height (0.6 cm) gain in treated children (age 2–
12 years) when compared to an untreated group at the 24-month
follow-up.The results werealsostatisticallysignificant when the 2- to
5-year age group was analysed separately [63].
In Zanzibar, children aged 6–59 months of age with a heavy
burden of helminth infections and malnutrition were studied during a
placebo-randomised trial to measure the effect of a daily low-dose iron
and/or 3-monthly STH treatment on growth, iron status, anaemia,
and development. At 12 months, the results found that periodic
mebendazole had reduced mild wasting malnutrition by 62% and
small arm circumference by 71% in children aged ,30 months. In all
children, their appetite had improved by 48% [17].
In Uganda, a randomised trial showed the weight of PSAC who
received albendazole every 6 months during Child Health Days
was 10% greater than in untreated controls (5% greater when the
treatment was given annually) [64].
In a series of studies in Indian urban slums, the delivery of
albendazole every 6 months reduced stunting by 9.4% and
improved weight by 35% in infants and PSAC within 2 years
[65,66]. A large-scale study then confirmed these findings [67],
and a significant weight gain and a 28% reduction in diarrhoea
episodes in PSAC were further observed following treatment with
albendazole [68].
In Kenya, treatment of sick, STH infected 2- to 4-year-olds with
a single dose of mebendazole through the Integrated Management
of Childhood Illness (IMCI) approach yielded statistically
significant height and weight gains at follow up after 6 months
[69,70]. The growth of Ascaris-infected PSAC in Kenya also
benefited from repeated levamisole treatments [71].
A few studies have failed to show any impact of deworming on
growth:
N A study from Bangladesh in children 2–6 years old who were
treated with mebendazole every 2 months did not show
improvement in weight, height, or mid arm circumference
when compared to the placebo group [72]. A high prevalence
of Giardia duodenalis in the treated group might account for the
poor outcomes.
N A trial in Mexico that examined the effects of albendazole
(400 mg or 1,200 mg) or pyrantel treatment on growth of
apparently healthy children (aged 2–10 years) infected with T.
trichiura did not show any significant difference in growth at a
12-month follow-up between the three drug regimens [73].
N In the Democratic Republic of the Congo (formerly Zaire),
deworming with mebendazole every 3 months did not
improve the growth of malnourished children aged 0–
72 months, whereas vitamin A supplements did have an effect
at a 12-month follow-up. In this study, however, the
prevalence of STH infections was low (10% A. lumbricoides at
baseline) and the manufacturer of the mebendazole was not
mentioned [74].
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A summary of published studies on the improvement in iron
status in PSAC following STH deworming is shown in Table 4.
In Zanzibar, the administration of mebendazole to children
,24 months every 3 months was shown to reduce moderate
anaemia (Hb,9 g/dl) by 59% after 12 months [17]. Preliminary
reports from a large scale trial (n=2,000 children aged 6–
23 months) carried out in 2005 in the same study area suggest a
significant decrease of wasting malnutrition and of moderate-
severe anaemia in the mebendazole treated group (Rebecca
Stoltzfus, personal communication).
In Nepal, a study in 2004 to evaluate the national biannual
vitamin A supplementation programme that has co-delivered STH
treatment since 1999 demonstrated an impressive drop in anaemia
Table 3. Impact of Anthelminthic Treatment on Growth of PSAC
Country
Sample
Size
Age
Range STH Treatment Schedule
Follow-Up
(Months) Outcome Reference
Myanmar 1,206 2–12 A T H LEV/3 months 24 0.93 kg more in weight, 0.6 cm more
in height compared with no treatment
[63]
Bangladesh 1,402 2–6 A T H MBD 500 mg/2 months 18 No improvement in weight, height,
or mid-arm circumference compared
with placebo.
[72]
Indonesia 289 2–5 A T ALB 400 mg+iron supplement 2 0.17 kg more in weight and no difference
in height compared with placebo.
[91]
Mexico 508 2–10 T ALB 400 mg or PYR 11 mg/kg/
4 months
12 After ALB 0.01 kg less in weight and
0.14 cm more in height than after PYR.
[73]
Tanzania 273 1–5 A LEV/3 months 12 Weight gain 21% greater than that in
those given a placebo.
[62]
Tanzania
(Zanzibar)
459 0.5–6 A T H MBD 500 mg/3 months 12 Mild wasting malnutrition reduced by
62% and small arm circumference by
71% in children ,30 months. Appetite
improved by 48% in all children.
[17]
Uganda 28,015 0–7 A T H ALB 400 mg/6 months 30 154 g weight gains of the treated group
compared with no treatment.
[64]
India 1,061 1.5–3.5 A ALB 400 mg/6 months 24 9.4% less stunting compared with placebo. [65]
India 702 2–5 A ALB/6 months 12 40% ALB treated children had .10%
weight gain compared with 29% of
placebo-treated children.
28% reduction in diarrohea episodes.
[68]
Kenya 574 2–4 A T H MBD 500 mg 6 0.44 kg weight gain, 0.78 cm height
gain, 0.28 weight for age (Z score)
gain, compared with placebo.
[70]
DR Congo
(formerly Zaire)
328 0–6 A T MBD 500 mg/3 months 12 No gain in weight nor in height compared
with no treatment.
[74]
A, A. lumbricoides; ALB, albendazole; H, hookworm; LEV, levamisole; MBD, mebendazole; T, T. trichiura.
doi:10.1371/journal.pntd.0000126.t003
Table 4. Impact of Anthelminthic Treatment on Iron Status and Vitamin A of PSAC
Country
Sample
Size
Age
Range STH Treatment Schedule
Follow-Up
(Months) Outcome Reference
Tanzania (Zanzibar) 459 0.5–6 A T H MBD 500 mg/3 months 12 Moderate anaemia (Hb ,9g / d l )
reduced by 59% in children aged
,24 months compared with placebo.
[17]
Nepal 1,635 2–5 A T H ALB 400 mg/6 months+vitamin A 12 Anaemia reduced by 77%. No
control group.
[75]
Indonesia 259 3–6 A LEV+beta carotene+fat meal 1 Serum retinol increased in Lev
group compared with beta
carotene+fat meal.
[76]
Indonesia 131 2.5–5 A T ALB+vitamin A 1 Vitamin A deficiency improved by
81% and anaemia reduced by 39%.
[77]
India 487 1–5 A L-tetramisole+vitamin A 12 Deworming did not augment the
beneficial effect of vitamin A.
Increment of vitamin A at follow
up in the ascaris +ves was 65% of
that of ascaris 2ves.
[78]
A, A. lumbricoides; ALB, albendazole; H, hookworm; MBD, mebendazole; T, T. trichiura.
doi:10.1371/journal.pntd.0000126.t004
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profound benefit could be attributed to the control of hookworm
infections and to the parallel delivery of vitamin A supplements, as
both interventions reduce anaemia.
Except for the two trials mentioned above, there are no other
studies that have examined the impact of regular anthelminthic
treatment on the iron status of PSAC living in hookworm-endemic
areas.
Vitamin A
A summary of published studies on the improvement of vitamin
A status in PSAC following STH deworming is shown in Table 4.
In Indonesia, two studies examined the impact of deworming on
vitamin A status. In the first study, fatty meals and beta-carotene
supplements were given to 3- to 6-year-old children infected with
STHs. A subgroup of these children was also dewormed with
levamisole. Dewormed children showed the highest rise in serum
retinol. Moreover, additional meal fat combined with STH
deworming increased serum retinol to the same degree as feeding
the children with additional beta carotene sources [76]. In the
second study, the vitamin A was given just before the deworming;
again, children cleared of A. lumbricoides or T. trichiura infections
showed a significantly improved vitamin A status at follow up [77].
In urban slums in Hyderabad, India, where A. lumbricoides is
endemic, a randomised study in 1- to 5-year-old children indicated
that deworming with L-tetramisole did not augment the beneficial
effects of vitamin A, and that deworming alone did not improve
their vitamin A status as compared to the placebo group. At the 1-
year follow-up, however, the vitamin A levels in the Ascaris-infected
group showed less improvement than those in the uninfected
group, although the results were not statistically significant [78].
Cognitive and motor development
Only a few studies have evaluated the impact of periodic
deworming on cognitive and motor development of PSAC due do
the difficulties of designing a well-controlled study and applying
cognitive tests and measuring standard development milestones in
this age group and in different socio-cultural settings.
In Zanzibar, periodic treatment of STH-infected PSAC
(n=417) with mebendazole had a positive, although not
statistically significant, effect on children’s motor and language
development; most of the effect was observed in children between
12 and 24 months of age [24].
In a Caribbean setting, repeated treatment with mebendazole
improved the mental development of trichuris-infected PSAC
aged 27–72 months suffering from TDS [79].
In India, a study of children aged 18–42 months (n=1,016) who
were divided into a treatment and control group showed no
difference in their cognitive performance following treatment with
albendazole twice yearly at a 24-month follow-up [65].
Experience from the Field: Scaling up Deworming by
Incorporating STH Control into Other Large-Scale Public
Health Interventions
The number of PSAC being dewormed is rapidly escalating due
to the fact that countries are adding deworming to established
large-scale programmes, including vitamin A supplementation
programmes, vaccination campaigns, and Child Health Days. The
advantage of these programmes is that they are often delivered
regularly, the anthelminthic drugs are safe (it is difficult to
overdose on them), and with proper training, their administration
is also straightforward (unlike injections, for example). For the
latter two reasons, anthelminthics can be given by trained non-
health staff. Co-delivery using an existing infrastructure also
reduces costs, improves access to difficult-to-reach communities,
and boosts overall coverage since a package of medications is
usually more appealing than a single one [6].
Although WHO’s reporting system has strengthened over
recent years, which partly explains the increase in numbers,
WHO estimates that 10 million PSAC were reached in 2003, 37
million in 2004, and nearly 50 million in 2005 [2]. Country reports
and data are collected by WHO and available on the Web [80].
Delivery Channels.
Vitamin A campaigns
The co-delivery of vitamin A capsules and STH deworming
tablets is a particularly logical union for several reasons. First, the
target age group is similar: vitamin A is given to children 6–
59 months of age and deworming to 12- to 59-month olds.
Second, vitamin A is delivered twice a year, which is the same
frequency required for STH deworming of PSAC if the prevalence
of infection is $50% in the school-age population. Third, vitamin
A programmes enjoy a high coverage. In 2004, approximately 190
million children received at least one high-dose vitamin A
supplement and global coverage reached 68% of targeted children
[81]. Fourth, if a child is vitamin A deficient, he/she is likely to be
also infected with worms given that both are common in the same
socio-economic conditions. Fifth, A. lumbricoides impairs the
absorption of vitamin A from the diet, either by competing for
vitamin A absorption with the host, or by leading to overall
malabsorption of vitamin A (and other micronutrients) in the gut;
this is especially true in chronic infections [11,20].
Supplementary immunization activities
Supplementary immunization activities (SIAs) are active
vaccination interventions that complement routine immunization
activities. Such interventions or campaigns are ongoing in many
countries and have extremely well-established delivery systems that
target all infants in their first years of life. Several countries have
taken advantage of their SIAs and have included STH deworming
as part of their measles and/or polio vaccination campaigns [82].
The benefit of using these campaigns (there are several types,
including catch-up, follow-up, and mop-up campaigns for measles,
and national and sub-national immunization days [NIDs and sub-
NIDs] for measles and polio) for delivering other products is that
they have an extensive coverage. Target groups for deworming
and vaccines are not the same but largely overlap: measles vaccine
is given from 9 months of age onwards (up to 59 months usually).
Polio targets 0- to 59-month-old children. The drawback is that
STH deworming must be delivered regularly, while measles
campaigns only take place every 3–4 years; polio NIDs or sub-
NIDs are usually more frequent, but less regular depending on
epidemiology of infection. Also, while coupling deworming tablets
with the oral polio vaccine does not pose significant logistical
problems to the community volunteers responsible for its
administration, some countries have voiced concerns that
deworming added to measles campaigns may jeopardize the
campaign (the measles vaccine is injected only by trained medical
personnel, which makes the burden of work per person high).
Child Health Days
Child Health Days and Child Health Weeks are regular and
systematic interventions aimed at improving access to, and use of,
routinely available health services [82]. They are becoming
increasingly popular as a way of reaching large numbers of
children under five years old as well as SAC (and sometimes
adults) in many countries. In Uganda, for example, different
baskets of products and services are co-delivered annually or
biannually, including vaccines, vitamin A supplements, deworm-
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including growth monitoring, antenatal care, and health education
and family planning, according to the needs of the country [83].
Routine health delivery services
Routine health delivery services are interventions taking places
at health centres all year round. Both EPI (Expanded Program on
Immunization) and IMCI (Integrated Management of Childhood
Illness) are examples of routine services. EPI provides routine
vaccinations according to the national immunization schedule.
Immunization carried out at health centres can be complemented
by outreach activities whereby mobile vaccinators regularly
(usually every month) visit dispersed communities so as to increase
vaccination coverage. Even if EPI mainly targets children in their
first year of life, in many developing countries a significant
proportion of children older than 1 year still have to complete
their vaccination schedule. In this circumstance, the EPI visit
represents a good opportunity for providing STH deworming
tablets.
The IMCI strategy aims to improve the routine clinical
management of PSAC; its approach includes the accurate
identification and management of illnesses in health facilities and
represents another delivery channel to reach PSAC. Treatment of
STH infection is included in the IMCI protocol: administration of
mebendazole treatment is recommended for sick children older
than 2 years with palmar pallor or with very low weight for age in
areas where hookworm and T. trichiura infections are endemic.
Successful examples of deworming through IMCI are reported
from Kenya and Mexico [69,70,84].
Schools and nurseries
Schools offer an excellent opportunity for reaching schoolchil-
dren, with the advantage that schoolteachers can be trained to
distribute anthelminthic drugs to their pupils. However, schools
can also represent an entry point into pupils’ families and the
wider community. Experience from Zanzibar showed that both
PSAC and non-enrolled SAC can be successfully reached through
the local school deworming programme [85]. It is worth noting
that in many African countries late school enrolment is common
and children often start primary school at the age of 8–9 years old
[86]. Where school enrolment or the number of schools is very
low. school-based distribution needs to be coupled with other
delivery channels. In some countries, like the Seychelles [87] and
South Africa [88], cre `ches and nurseries have been successfully
used to reach PSAC.
Community-based anthelminthic interventions
These are interventions utilizing community members as
distributors of anthelminthic drugs. Such interventions are
commonly implemented when entire communities—and not
specific population groups—are targeted for treatment, such as
in the case of onchocerciasis control (community-directed
treatment with ivermectin [CDTI]) and lymphatic filariasis
elimination (mass drug administration [MDA], with either
ivermectin+albendazole or DEC+albendazole). According to the
drug(s) being delivered, PSAC (defined slightly differently
according to the programme in question) are included among
those eligible for treatment [9]. Under the lymphatic filariasis
programme, a child, by default, is covered for STH infection
through the albendazole component of the drug combination.
Whereas under the onchocerciasis programme, which only
delivers ivermectin (ivermectin is not recommended for STH
control due to its suboptimal effect against the STH parasites [9]),
the simultaneous distribution of albendazole for STH deworming
could be considered, which would take advantage of the
established onchocerciasis delivery channel. The drawback of
Table 5. Research and Operational Challenges
Further assessment of the risk/benefits of
deworming PSAC for STH
Iron status: The impact of deworming on the iron status of PSAC needs to be further documented and stronger
evidence should be published from large-scale studies.
Cognitive development: The impact of periodic STH treatment on the mental, motor and language
development of PSAC needs to be confirmed and properly tested in different epidemiological settings.
Outreach/cost/feasibility Innovative ways of outreaching and delivering STH deworming to PSAC—alone or with other
medications—should be documented, with particular attention to feasibility and cost-effectiveness. It is essential
that such approaches are properly monitored and evaluated at country level, and their successes documented in
order to enhance advocacy and guide international agencies and policy makers to promote appropriate tools for
the control of STH infections and other diseases in children.
Monitoring safety 1- to 3–year-old children and tablet size: Adverse Event Reporting Forms (AERS) need to be included in any
campaign delivering anthelminthic drugs so as to routinely capture data on the number of children having
problems with swallowing tablets. In the meantime, WHO and UNICEF should continue advocating for the
development of novel paediatric formulations (rapid dissolving tablets).
Pharmacovigilance: Safety of giving anthelminthics with other drugs in population-based interventions needs
to be evaluated in large-scale control programmes by a review of observational evidence.
Monitoring drug efficacy Drug efficacy of anthelminthic drugs delivered in large-scale interventions and the early occurrence of
treatment failures needs to be monitored; any suspect episode of drug resistance should be properly reported.
Monitoring coverage An integrated monitoring system to collect and manage data related to the number of children treated (both
PSAC and SAC) needs to be developed to report on coverage of different age and high risk groups.
Evaluating interactions Vaccine interactions: Possible synergies and interactions related to delivering anthelminthics with different
vaccines (measles, BCG, polio) in large-scale vaccination campaigns needs to be further evaluated and properly
followed up in the mid and long term.
Malaria/TB/HIV: Interactions of STH infections with the management of the three big killers—malaria, TB, and
HIV—needs further study and science-based evidence to advocate and suggest novel means of combating
malaria, TB, and HIV infections in STH-endemic areas.
doi:10.1371/journal.pntd.0000126.t005
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onchocerciasis is that they usually take place once a year, which
may not be sufficient to effectively control STH infection in
high-risk communities where two yearly distributions are recom-
mended [9]. Where school enrolment is low, community-based
distributors are also used to treat SAC and other eligible children
who are not yet at school with other anthelminthics such as
praziquantel [89].
Conclusion: Need for Further Science-Based Evidence
Periodic treatment with anthelminthics has become one of the
most popular and successful public health interventions taking
place in STH-endemic countries. This paper has endeavoured to
summarize the published evidence and country experiences that
support and justify the inclusion of pre-school children in these
programmes. In conclusion, both sources of information support
the recommendation that PSAC should indeed be regularly
dewormed where the epidemiological situation merits such action.
The published literature clearly shows that PSAC infected with
STHs benefit both in terms of their health and development and
also in terms of reaching their cognitive potential. Country
experiences demonstrate that the addition of deworming to large-
scale public health programmes is not only feasible, but also makes
sense on a number of practical fronts. However, this trend also
raises a number of important issues that should be addressed by
the scientific community: (i) monitoring safe administration of the
deworming tablets in children 1–3 years old needs to be
strengthened; (ii) more appropriate paediatric formulations need
serious research and development; (iii) stronger economic analysis
and evidence to assess the cost-effectiveness of deworming PSAC is
needed; (iv) more research on the interaction of anthelminthics
with vaccines is needed; and (v) more research on how STH
infections impact the health of a person co-infected with
tuberculosis, malaria, and HIV is required. Some open
research questions and operational challenges that would need
further consideration in the public health agenda are described
in Table 5.
Box 1. Search Strategy and Selection Criteria
Most information for this Review comes from published
literature. References were identified through Medline
searches between 1969 and 2007. The general search
terms used were ‘‘helminths’’ and ‘‘children’’. The following
specific search terms were then used: ‘‘helminths and
anaemia’’, ‘‘helminths and vitamin A’’, ‘‘helminths and
malnutrition’’, ‘‘helminths and malaria’’, ‘‘helminths
and HIV’’, ‘‘helminths and TB’’, and ‘‘helminths and
vaccine’’. Other information was sourced from relevant
documents published by WHO, Geneva. Some information,
particularly relating to country experiences, was extracted
from grey literature and from unpublished country reports
in the WHO Global Databank on schistosomiasis and STH.
Box 2. Learning Points
1. More than 200 million pre-school-age (PSAC) children are
infected by soil-transmitted helminths (STHs), which
affects their iron and vitamin A status, and impairs their
nutrition, growth, and cognitive development.
2. Safety tested and effective anthelminthic drugs with a
significant impact on worm burden and disease-associ-
ated morbidity are available for administration to
children over 1 year of age.
3. PSAC infected by STHs benefit from preventive treatment
with anthelminthics, and country experiences demon-
strate that almost 50 million PSAC worldwide have been
dewormed for STHs in 2006 through large-scale inter-
ventions such as vitamin A and immunization campaigns,
Child Health Days, routine health delivery services,
schools, nurseries, and community-based interventions.
4. A number of open research questions and operational
challenges still need to be addressed, such as monitoring
the safety of tablet administration in children 1–3 years
old and advocacy for new paediatric formulations,
further assessment of the cost-effectiveness of deworm-
ing PSAC, and interactions with vaccines and with co-
infection with tuberculosis, malaria, and HIV.
Box 3. Key Papers
1. Albonico M, Crompton DW, Savioli L (1999) Control
strategies for human intestinal nematode infections. Adv
Parasitol 42: 277–341.
2. Stoltzfus RJ, Chwaya HM, Montresor A, Tielsch JM, Jape
Khatib J, Albonico M, Savioli L (2004) Low dose daily iron
supplementation improves iron status and appetite but
not anemia, whereas quarterly anthelminthic treatment
improves growth, appetite and anemia in Zanzibari pre-
school children. J Nutr 134: 348–356.
3. Montresor A, Awashti S, Crompton DWT (2003) Use of
benzimidazoles in children younger than 24 months for
the treatment of soil-transmitted helminthiasis. Acta Trop
86: 223–232.
4. WHO and UNICEF (2004) How to add deworming to
vitamin A distribution. Geneva: World Health Organiza-
tion.
5. WHO (2006) Schistosomiasis and soil-transmitted hel-
minth infections–preliminary estimates of the number of
children treated with albendazole or mebendazole. Wkly
Epidemiol Rec 16: 145–164.
6. WHO (2007) WHO Global Databank on schistosomiasis
and soil-transmitted helminth infections. Geneva: World
Health Organization. Available: http://www.who.int/
wormcontrol/databank/en/. Accessed 2 March 2008.
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